---
title: "Latigo Biotherapeutics files initial beneficial ownership statement for Sanofi"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295662614.md"
description: "Sanofi filed a Form 3 with the SEC, disclosing an initial beneficial ownership stake of 10% in Latigo Biotherapeutics as of August 6, 2026. The filing details indirect ownership of 494,800 shares of Series B Preferred Stock and 177,978 shares underlying a Convertible Promissory Note."
datetime: "2026-08-12T12:10:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295662614.md)
  - [en](https://longbridge.com/en/news/295662614.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295662614.md)
generator: "portal-rs"
---

# Latigo Biotherapeutics files initial beneficial ownership statement for Sanofi

-   Sanofi filed a Form 3 disclosing 10% ownership in Latigo Biotherapeutics as of Aug. 6, 2026. \* Indirect beneficial ownership of 494,800 shares underlying Series B Preferred Stock. \* Indirect beneficial ownership of 177,978 shares underlying a Convertible Promissory Note. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Latigo Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-345811), on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [LTGO.US](https://longbridge.com/en/quote/LTGO.US.md)
- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)

## Related News & Research

- [Sino Biopharm CEO Tse says AI, internationalization anchor counter-cyclical growth strategy](https://longbridge.com/en/news/298258012.md)
- [Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth](https://longbridge.com/en/news/298795959.md)
- [First Breach files Form 3 showing director Robert Charles Brandt stake of 34,247 shares](https://longbridge.com/en/news/298649951.md)
- [AdaptHealth files Form 3 showing CFO Harriss T. Currie as beneficial owner](https://longbridge.com/en/news/298765282.md)
- [Interactive Strength files Form 3 showing Thomas Barclay Aulet stake of 791,735 shares](https://longbridge.com/en/news/298598501.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**